

# Trastuzumab Biosimilars Market Trends: Major Players Are Investing In New Product Launches And Strategic Partnerships

*The Business Research Company's Global Trastuzumab Biosimilars Market Report 2020-30: Covid 19 Growth And Change*


LONDON, GREATER LONDON, UK,  
September 22, 2020 /

EINPresswire.com/ -- Major players in the trastuzumab biosimilars market are continuously focusing on launching new products in untapped regions, which is shaping the market for trastuzumab biosimilars. The companies operating in the trastuzumab biosimilars market are undergoing various strategic initiatives such as new product development, partnerships, and geographical and product portfolio expansion to maintain their competitive position in the market and better serve the needs of the customers.

For instance, in December 2019, Biocon and Mylan launched Ogivri (trastuzumab-dkst) - a trastuzumab biosimilar - in the USA. Mylan plans to offer Ogivri in 150 mg and 420 mg strengths, and increase access for the treatment of HER2-positive breast and gastric cancer. In February 2020, Pfizer launched trastuzumab biosimilar to Herceptin, Trazimera in the USA. Trazimera is available for the treatment of human epidermal growth factor receptor 2 (HER2) metastatic gastric and breast cancer.

Furthermore, in April 2020, Merck announced the launch of a Biosimilar of Herceptin (trastuzumab) - ONTRUZANT (trastuzumab-dttb). ONTRUZANT is available in the USA for approximately \$1,325 and \$3,709 for the 150 mg single-dose and 420 mg multiple-dose vial, respectively.

[The global trastuzumab biosimilars market size](#) is expected to decline from \$1.27 billion in 2019 to \$1.25 billion in 2020 at a compound annual growth rate (CAGR) of -1.50%. The decline is mainly due to the COVID-19 outbreak that has led to restrictive containment measures involving



social distancing, remote working, and the closure of industries and other commercial activities resulting in operational challenges.

The entire supply chain has been disrupted, impacting the market negatively. [The trastuzumab biosimilars market share](#) is then expected to recover and reach \$3.12 billion in 2023 at a CAGR of 35.50%.

The rising prevalence of breast and gastric cancer contributed to the growth of the trastuzumab biosimilar market size. Trastuzumab biosimilar is used in the treatment of human epidermal growth factor receptor 2 (HER2) overexpressing breast cancer and metastatic gastric cancer.

According to the World Health Organization (WHO), in 2018, the new breast cancer cases registered were around 2.09 million, and stomach (gastric) cancer cases were around 1.03 million. According to Cancer India, breast cancer is the most common cancer in women in India and accounts for 14% of the cancers in women. Therefore, the rising prevalence of breast and gastric cancer increases the demand for trastuzumab biosimilar that helps save money when compared to expensive medicines, thereby driving the trastuzumab market industry.

The trastuzumab biosimilar market share consists of the sales of trastuzumab biosimilar and related services by entities (organizations, sole traders, and partnerships) that manufacture trastuzumab biosimilars. Trastuzumab is a monoclonal antibody that interferes with human epidermal growth factor receptor (HER2). Trastuzumab biosimilars are used mainly for the treatment of breast cancer and gastroesophageal junction adenocarcinoma or metastatic gastric.

The global trastuzumab biosimilars market share is segmented by product into ogivri, herzuma, ontruzant, trazimera, and others. By indication, the market is segmented into adjuvant breast cancer, metastatic breast cancer, metastatic gastric cancer, and others. By distribution channel, it is segmented into hospital pharmacy and online pharmacy.

Here Is A List Of Similar Reports By The Business Research Company:

Breast Cancer Drugs Global Market Report 2020-30: Covid 19 Impact And Recovery (<https://www.thebusinessresearchcompany.com/report/breast-cancer-drugs-global-market-report>)

Gastric Cancer Drugs Global Market Report 2020-30: Covid 19 Impact And Recovery (<https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report>)

HER2 Inhibitors Market Market Global Report 2020-30: Covid 19 Growth And Change (<https://www.thebusinessresearchcompany.com/report/her2-inhibitors-market-market-global-report-2020-30-covid-19-growth-and-change>)

Oncology Biosimilars Market Global Report 2020

<https://www.thebusinessresearchcompany.com/report/oncology-biosimilars-market-global-report>

Biosimilars Market Global Report 2020

<https://www.thebusinessresearchcompany.com/report/biosimilars-market-global-report>

Interested to know more about [The Business Research Company?](#)

The Business Research Company is a market intelligence firm that excels in company, market, and consumer research. Located globally it has specialist consultants in a wide range of industries including manufacturing, healthcare, financial services, chemicals, and technology.

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

[email us here](#)

Visit us on social media:

[Facebook](#)

[Twitter](#)

[LinkedIn](#)

---

This press release can be viewed online at: <https://www.einpresswire.com/article/526767539>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2020 IPD Group, Inc. All Right Reserved.